$1.09
arrow_drop_down0.90%Key Stats | |
---|---|
Open | $1.09 |
Prev. Close | $1.10 |
EPS | -0.09 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
Market Cap | $125.58M |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 1.05 | 1.14 |
52 Week Range | 0.66 | 3.98 |
Ratios | |
---|---|
Revenue | - |
EPS | -0.09 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Hepatic Tumor Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 75+ Companies Working in the Domain
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
Pfizer: Seriously Undervalued At Peak Pessimism
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update